H.R. 1414: Cameron’s Law

H.R. 1414 is a federal bill in the 119th Congress. Drug companies developing treatments for rare diseases currently receive a tax credit equal to 25 percent of their clinical testing expenses. Under this change, that credit increases to 50 percent of those expenses, returning the rate to what it was before… See its sponsors, how members voted, and a plain-English breakdown on PolityLens.